LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 3143

Search options

  1. Article: A propos d'un cas de lupus tuberculeux après vaccination par le B.C.G.

    Ndiaye, B / Ball, M D / Diop, E M / Strobel, M / Marchand, J P

    Dakar medical

    1982  Volume 27, Issue 2, Page(s) 187–191

    Title translation A case of tuberculous lupus following BCG vaccination.
    MeSH term(s) BCG Vaccine/adverse effects ; Child, Preschool ; Female ; Humans ; Lupus Vulgaris/etiology
    Chemical Substances BCG Vaccine
    Language French
    Publishing date 1982
    Publishing country Senegal
    Document type Case Reports ; Journal Article
    ZDB-ID 449749-1
    ISSN 0049-1101 ; 0850-797X
    ISSN 0049-1101 ; 0850-797X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 846: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Use of cytosol-depleted HL-60 cells for reconstitution studies of G-protein-regulated phosphoinositide-specific phospholipase C-beta isozymes.

    Cockcroft, S / Thomas, G M / Cunningham, E / Ball, A

    Methods in enzymology

    1994  Volume 238, Page(s) 154–168

    MeSH term(s) Bacterial Proteins ; Cell Line ; Cell Membrane Permeability ; Cytosol/physiology ; Electrophoresis, Polyacrylamide Gel ; GTP-Binding Proteins/physiology ; Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology ; Homeostasis ; Humans ; Indicators and Reagents ; Isoenzymes/isolation & purification ; Isoenzymes/metabolism ; Kinetics ; Leukemia, Promyelocytic, Acute ; Phosphatidylinositol Diacylglycerol-Lyase ; Phosphoric Diester Hydrolases/isolation & purification ; Phosphoric Diester Hydrolases/metabolism ; Radioisotope Dilution Technique ; Streptolysins ; Tritium ; Tumor Cells, Cultured
    Chemical Substances Bacterial Proteins ; Indicators and Reagents ; Isoenzymes ; Streptolysins ; streptolysin O ; Tritium (10028-17-8) ; Guanosine 5'-O-(3-Thiotriphosphate) (37589-80-3) ; Phosphoric Diester Hydrolases (EC 3.1.4.-) ; GTP-Binding Proteins (EC 3.6.1.-) ; Phosphatidylinositol Diacylglycerol-Lyase (EC 4.6.1.13)
    Language English
    Publishing date 1994
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 0076-6879
    ISSN 0076-6879
    DOI 10.1016/0076-6879(94)38014-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Phospholipase C beta2 association with phospholipid interfaces assessed by fluorescence resonance energy transfer. G protein betagamma subunit-mediated translocation is not required for enzyme activation.

    Romoser, V / Ball, R / Smrcka, A V

    The Journal of biological chemistry

    1996  Volume 271, Issue 41, Page(s) 25071–25078

    Abstract: Phospholipase C beta2 (PLC beta2) is activated by G protein betagamma subunits and calcium ... enzymatic activity and ability to be regulated by G proteins. Using this method it was found that PLC beta2 bound ... by D-myo-inositol 1,4,5-trisphosphate (D-IP3). G protein betagamma subunits do not alter the affinity ...

    Abstract Phospholipase C beta2 (PLC beta2) is activated by G protein betagamma subunits and calcium. The enzyme is soluble and its substrate, phosphatidylinositol 4,5-bisphosphate (PIP2), is present in phospholipid membranes. A potential mechanism for regulation of this enzyme is through influencing the equilibrium association of the enzyme with membrane surfaces. In this paper we describe a fluorescence resonance energy transfer (FRET) method for measuring the association of PLC beta2 with phospholipid bilayers. The method allows equilibrium measurements to be made under a variety of conditions, including those that support enzymatic activity and ability to be regulated by G proteins. Using this method it was found that PLC beta2 bound to vesicles containing anionic lipids and demonstrated a selective and unique interaction with PIP2-containing vesicles. The FRET data were corroborated with a centrifugation based method for estimating the affinity of PLC beta2 for vesicles. Apparently different modes of association of PLC beta2 with vesicles of different composition can be distinguished based on alterations in resonance energy transfer efficiency. Association of PLC beta2 with PIP2 vesicles requires an intact lipid bilayer, is blocked by neomycin, and is not affected by D-myo-inositol 1,4,5-trisphosphate (D-IP3). G protein betagamma subunits do not alter the affinity of PLC beta2 for lipid bilayers and at the PIP2 concentrations used to measure betagamma-dependent stimulation of PLC activity, the majority of the PLC beta2 is already associated with the vesicle surface. Furthermore, under conditions where betagamma subunits strongly activate PLC activity, the extent of association with vesicles is unaffected by betagamma subunits or calcium. These results indicate that activation of PLC beta2 by G protein betagamma subunits or Ca2+ in vitro does not involve translocation to the vesicle surface.
    MeSH term(s) Animals ; Cell Line ; Cloning, Molecular ; Detergents/pharmacology ; Energy Transfer ; Enzyme Activation ; GTP-Binding Proteins/metabolism ; Isoenzymes/chemistry ; Isoenzymes/isolation & purification ; Isoenzymes/metabolism ; Kinetics ; Lipid Bilayers ; Phosphatidylinositol 4,5-Diphosphate/metabolism ; Phospholipase C beta ; Phospholipids/metabolism ; Recombinant Proteins/chemistry ; Recombinant Proteins/isolation & purification ; Recombinant Proteins/metabolism ; Spectrometry, Fluorescence ; Spodoptera ; Transfection ; Type C Phospholipases/chemistry ; Type C Phospholipases/isolation & purification ; Type C Phospholipases/metabolism
    Chemical Substances Detergents ; Isoenzymes ; Lipid Bilayers ; Phosphatidylinositol 4,5-Diphosphate ; Phospholipids ; Recombinant Proteins ; Type C Phospholipases (EC 3.1.4.-) ; Phospholipase C beta (EC 3.1.4.11) ; GTP-Binding Proteins (EC 3.6.1.-)
    Language English
    Publishing date 1996-10-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2997-x
    ISSN 1083-351X ; 0021-9258
    ISSN (online) 1083-351X
    ISSN 0021-9258
    DOI 10.1074/jbc.271.41.25071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uc I Zs.108: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions.

    Hendrickson, Barbara A / McShea, Cynthia / Ball, Greg / Talbot, Susan

    Therapeutic innovation & regulatory science

    2024  

    Abstract: In June 2021, FDA released a Draft Guidance on Sponsor Responsibilities for IND Safety Reporting and cited components of a recommended Safety Surveillance Plan (SSP). To meet the expectations of the 2021 FDA guidance, sponsors should document their plan ... ...

    Abstract In June 2021, FDA released a Draft Guidance on Sponsor Responsibilities for IND Safety Reporting and cited components of a recommended Safety Surveillance Plan (SSP). To meet the expectations of the 2021 FDA guidance, sponsors should document their plan for aggregate safety assessment. The Drug Information Association-American Statistical Association Interdisciplinary Safety Evaluation scientific working group has proposed an Aggregate Safety Assessment Plan (ASAP) that addresses this recommendation. The 2021 FDA guidance also discusses potential strategies for unblinded review of safety data from ongoing studies by an independent Assessment Entity, which could occur via planned periodic evaluations or "triggered" reviews based on blinded data assessments. The Assessment Entity reviewing unblinded data makes recommendations as to whether the threshold has been met for submission of an aggregate IND safety report. In this paper, we discuss how the ASAP supports IND aggregate safety reporting decisions, including elements to be included in a proposed SSP appendix to the ASAP. In addition, the authors advocate for the benefits of developing a charter (or specific section of the Data Monitoring Committee charter, if applicable) that describes the responsibilities and conduct of the Assessment Entity. With these components in place, study sponsors will meet the objective of having clearly defined processes for the monitoring of clinical trial safety data in aggregate and making IND safety reporting decisions.
    Language English
    Publishing date 2024-03-30
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2708397-4
    ISSN 2168-4804 ; 2168-4790
    ISSN (online) 2168-4804
    ISSN 2168-4790
    DOI 10.1007/s43441-024-00634-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: The art of the second opinion.

    Ball, Chad G / Schieman, Colin / Harvey, Edward J

    Canadian journal of surgery. Journal canadien de chirurgie

    2023  Volume 66, Issue 3, Page(s) E337–E338

    MeSH term(s) Humans ; Referral and Consultation ; Patient Satisfaction
    Language English
    Publishing date 2023-06-27
    Publishing country Canada
    Document type Editorial
    ZDB-ID 410651-9
    ISSN 1488-2310 ; 0008-428X
    ISSN (online) 1488-2310
    ISSN 0008-428X
    DOI 10.1503/cjs.007423
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 221: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases.

    O'Farrell, R / Maguire, S / Moore, L / Murray, K / Gorman, A / Ball, E / Riddell, C / O'Neill, M / Jordan, N / O'Shea, F / Veale, D / Donnelly, S / Murphy, G / Fitzgerald, G

    Irish medical journal

    2024  Volume 117, Issue 1, Page(s) 894

    MeSH term(s) Pregnancy ; Female ; Humans ; Pregnant Women ; Musculoskeletal Diseases/therapy
    Language English
    Publishing date 2024-01-18
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 193134-9
    ISSN 0332-3102 ; 0021-129X
    ISSN 0332-3102 ; 0021-129X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 148: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Correction to: Feasibility of intraoperative ultrasound of the small bowel during Crohn's disease surgery.

    Celentano, V / Beable, R / Ball, C / Flashman, K G / Reeve, R / Fogg, C / Harper, M / Higginson, A

    Techniques in coloproctology

    2023  Volume 27, Issue 4, Page(s) 343

    Language English
    Publishing date 2023-02-06
    Publishing country Italy
    Document type Published Erratum
    ZDB-ID 2083309-X
    ISSN 1128-045X ; 1123-6337
    ISSN (online) 1128-045X
    ISSN 1123-6337
    DOI 10.1007/s10151-023-02760-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5842: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Primary skin closure after damage control laparotomy (Br J Surg 2015: 102: 67-75).

    Ball, C G

    The British journal of surgery

    2015  Volume 102, Issue 1, Page(s) 76

    MeSH term(s) Humans ; Laparotomy/methods ; Surgical Wound Infection/prevention & control ; Wound Closure Techniques
    Language English
    Publishing date 2015-01
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 2985-3
    ISSN 1365-2168 ; 0263-1202 ; 0007-1323 ; 1355-7688
    ISSN (online) 1365-2168
    ISSN 0263-1202 ; 0007-1323 ; 1355-7688
    DOI 10.1002/bjs.9718
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uk I Zs.66: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Heterodimerization of Chemoreceptors TAS1R3 and mGlu

    Ball, Lena / Bauer, Julia / Krautwurst, Dietmar

    International journal of molecular sciences

    2023  Volume 24, Issue 16

    Abstract: ... other class-C G protein-coupling receptors (GPCRs), TAS1Rs and mGlu receptors form heteromers ... by means of immunocytochemistry and co-IP/Western analysis, that across class-C GPCR families, mGlu ...

    Abstract The expression of canonical chemosensory receptors of the tongue, such as the heteromeric sweet taste (TAS1R2/TAS1R3) and umami taste (TAS1R1/TAS1R3) receptors, has been demonstrated in many extra-oral cells and tissues. Gene expression studies have revealed transcripts for all TAS1 and metabotropic glutamate (mGlu) receptors in different types of immune cells, where they are involved, for example, in the chemotaxis of human neutrophils and the protection of T cells from activation-induced cell death. Like other class-C G protein-coupling receptors (GPCRs), TAS1Rs and mGlu receptors form heteromers within their families. Since mGlu receptors and TAS1R1/TAS1R3 share the same ligand, monosodium glutamate (MSG), we hypothesized their hitherto unknown heteromerization across receptor families in leukocytes. Here we show, by means of immunocytochemistry and co-IP/Western analysis, that across class-C GPCR families, mGlu
    MeSH term(s) Humans ; Glutamates ; HEK293 Cells ; Leukocytes ; Sodium Glutamate ; Receptors, G-Protein-Coupled/chemistry ; Receptors, G-Protein-Coupled/metabolism ; Receptors, Metabotropic Glutamate/chemistry ; Receptors, Metabotropic Glutamate/metabolism
    Chemical Substances Glutamates ; Sodium Glutamate (W81N5U6R6U) ; metabotropic glutamate receptor 2 ; taste receptors, type 1 ; Receptors, G-Protein-Coupled ; Receptors, Metabotropic Glutamate
    Language English
    Publishing date 2023-08-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms241612942
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.

    Hillis, Christopher / Vicente, Colin / Ball, Graeme

    PharmacoEconomics

    2022  Volume 40, Issue 9, Page(s) 917–928

    Abstract: Background and objective: Axicabtagene ciloleucel (axi-cel) received marketing authorisation in Canada for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and the clinical and economic value of ... ...

    Abstract Background and objective: Axicabtagene ciloleucel (axi-cel) received marketing authorisation in Canada for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and the clinical and economic value of axi-cel to patients and the healthcare system should be examined. The objective of this analysis is to determine, from societal and public healthcare payer perspectives, the cost effectiveness of axi-cel versus best supportive care for patients with relapsed or refractory large B-cell lymphoma in Canada.
    Methods: A pharmacoeconomic model was developed and populated with clinical data derived from the ZUMA-1 and SCHOLAR-1 studies using a propensity score-matched comparison. A partitioned survival mixture-cure modelling approach was taken to characterise the potential curative effect of axi-cel therapy in large B-cell lymphoma. Healthcare resource utilisation and adverse event data were based on results from ZUMA-1, and utility values were derived from ZUMA-1 data supplemented with published literature. Costs (in 2021 Canadian dollars) were taken from publicly available Canadian cost databases and published literature. Benefits and costs were discounted at 1.5% per year, and sensitivity analyses were conducted to assess the robustness of the results.
    Results: In the base case, axi-cel generated an incremental 6.2 life-years compared to best supportive care, corresponding to 4.6 additional quality-adjusted life-years, and was associated with $606,010 in additional costs. The incremental cost-utility ratio was $132,747 per quality-adjusted life-year gained compared with best supportive care from a societal perspective ($106,392 per quality-adjusted life-year gained from a public healthcare payer perspective). Key drivers of the analysis included progression-free survival and overall survival values for axi-cel.
    Conclusions: The results of this analysis suggest that axi-cel may be considered a cost-effective allocation of resources compared with best supportive care for the treatment of adult patients with relapsed or refractory large B-cell lymphoma in Canada.
    MeSH term(s) Adult ; Antigens, CD19/adverse effects ; Biological Products/therapeutic use ; Canada ; Cost-Benefit Analysis ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy
    Chemical Substances Antigens, CD19 ; Biological Products ; axicabtagene ciloleucel (U2I8T43Y7R)
    Language English
    Publishing date 2022-07-18
    Publishing country New Zealand
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1100273-6
    ISSN 1179-2027 ; 1170-7690
    ISSN (online) 1179-2027
    ISSN 1170-7690
    DOI 10.1007/s40273-022-01169-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3579: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top